TNFSF11 and osteogenesis imperfecta: Other antiresorptive therapies using monoclonal antibodies, such as Denosumab, against receptor activator of nuclear factor kappa-B ligand, Romosozumab against sclerostin (negative regulator of bone formation) or Odanacatib against cathepsin K (involved in the degradation of type I collagen) are currently under investigation in OI [50,51,52].